RESUMO
BACKGROUND: Heavy metals such as lead (Pb) and cadmium (Cd) have been associated with adverse pregnancy and developmental outcomes, including congenital abnormalities. This study investigated the association between exposure to heavy metals and trace elements during fetal life and congenital limb abnormalities in infants. METHODS: This study is based on a prospective ongoing nationwide birth cohort from the Japan Environment and Children's Study (JECS). The concentrations of Cd, Pb, mercury (Hg), selenium (Se), and manganese (Mn) were measured in maternal blood collected during the mid-late trimesters. Inclusion criteria were available from questionnaires filled in during pregnancy, including information about congenital limb abnormalities at birth or at one month. To examine the associations with limb anomalies and individual chemicals, logistic regression models were applied following log-transformation or division into quartiles of Cd, Pb, Hg, Se, and Mn concentrations. To assess the associations with the heavy metals and trace elements mixture, quantile g-computation was employed. All models were adjusted for age, maternal smoking history, maternal alcohol intake, history of smoking, and infant sex. RESULTS: Data from 90,163 participants were included in the analysis, of whom 369 had congenital limb abnormalities in any of the collected information, and 89,794 had none. Among the 369 cases of congenital limb abnormalities, there were 185 and 142 cases of polydactyly and syndactyly, respectively. The median concentrations of Pb, Cd, Hg, Se, and Mn were 5.85, 0.66, 3.64, 168, and 15.3 ng/g, respectively. There were no associations between maternal blood concentrations of Pb [adjusted odd ratio = 0.83; 95% confidence interval = 0.61, 1.11], Cd [0.87; 0.68, 1.10], Hg [0.88; 0.73, 1.07], Se [1.07; 0.44, 2.59], and Mn [0.91; 0.64, 1.30] with congenital limb abnormalities. No significant association was observed between the mixture of heavy metals and trace elements [0.85; 0.72, 1.02] and any congenital limb abnormalities. Moreover, there was no association with all polydactylies and all syndactylies, or any type of abnormality as a subdivision. CONCLUSION: At the maternal exposure levels of Cd, Pb, Hg, Se, and Mn assessed in the present study, no association was identified with the risk of developing congenital limb abnormalities in children.
Assuntos
Poluentes Ambientais , Deformidades Congênitas dos Membros , Exposição Materna , Metais Pesados , Oligoelementos , Humanos , Japão/epidemiologia , Feminino , Metais Pesados/sangue , Oligoelementos/sangue , Oligoelementos/deficiência , Recém-Nascido , Masculino , Prevalência , Gravidez , Deformidades Congênitas dos Membros/epidemiologia , Deformidades Congênitas dos Membros/sangue , Deformidades Congênitas dos Membros/induzido quimicamente , Exposição Materna/efeitos adversos , Exposição Materna/estatística & dados numéricos , Poluentes Ambientais/sangue , Adulto , Estudos ProspectivosRESUMO
The Hedgehog (Hh) signalling pathway is essential for cellular proliferation and differentiation during embryonic development. Gain and loss of function of Hh signalling are known to result in an array of craniofacial malformations. To determine the critical period for Hh pathway antagonist-induced frontal bone hypoplasia, we examined patterns of dysmorphology caused by Hh signalling inhibition. Pregnant mice received a single oral administration of Hh signalling inhibitor GDC-0449 at 100 mgâ¢kg-1 or 150 mgâ¢kg-1 body weight at preselected time points between embryonic days (E)8.5 and 12.5. The optimal teratogenic concentration of GDC-0449 was determined to be 150 mgâ¢kg-1. Exposure between E9.5 and E10.5 induced frontal bone dysplasia, micrognathia and limb defects, with administration at E10.5 producing the most pronounced effects. This model showed decreased ossification of the frontal bone with downregulation of Hh signalling. The osteoid thickness of the frontal bone was significantly reduced. The amount of neural crest-derived frontal bone primordium was reduced after GDC-0449 exposure owing to a decreased rate of cell proliferation and increased cell death.
Assuntos
Anilidas/farmacologia , Doenças do Desenvolvimento Ósseo/induzido quimicamente , Osso Frontal/anormalidades , Proteínas Hedgehog/antagonistas & inibidores , Deformidades Congênitas dos Membros/induzido quimicamente , Osteogênese/efeitos dos fármacos , Piridinas/farmacologia , Transdução de Sinais/efeitos dos fármacos , Administração Oral , Animais , Proliferação de Células/efeitos dos fármacos , Proliferação de Células/fisiologia , Feminino , Camundongos , Micrognatismo/induzido quimicamente , GravidezRESUMO
Thalidomide remains notorious as a result of the damage it caused to children born to mothers who used it to treat morning sickness between 1957 and 1961. The re-emergence of the drug to treat a range of conditions including erythema nodosum leprosum (a complication of leprosy) has led to a new generation of thalidomide damaged children being born in Brazil. Although thalidomide affects most of the developing tissues and organs of the body, the damage to the limbs is striking. Indeed phocomelia, the severe reduction or loss of the proximal long bones with retention of the distal hand/foot plate remains the stereotypical image of thalidomide. This review focuses on the type and range of damage thalidomide caused to the limbs, reviews current understanding of the mechanisms underlying thalidomide-induced limb malformations and outlines some of the challenges remaining in elucidating its teratogenicity.
Assuntos
Deformidades Congênitas dos Membros/induzido quimicamente , Teratogênicos/farmacologia , Talidomida/efeitos adversos , Anormalidades Induzidas por Medicamentos/história , Extremidades/embriologia , Feminino , História do Século XX , História do Século XXI , Humanos , Botões de Extremidades/embriologia , Gravidez , Teratogênese/efeitos dos fármacos , Talidomida/farmacologiaRESUMO
Thalidomide embryopathy results from the ingestion of thalidomide in the first trimester during pregnancy, causing multiple forms of congenital abnormalities of variable severity that involve all systems. The skeletal findings most frequently affect the limbs, particularly the upper limbs and hands. Increasingly, several genetic disorders with similar birth defects have been identified. New cases of malformations owing to possible exposure to thalidomide continue to present through both historical and current usage. However, inadequate proof of ingestion, marked phenotypic variation and the possibility of an alternative genetic condition, hinder the diagnosis of thalidomide embryopathy. We introduce a 'diagnostic algorithm for thalidomide embryopathy' (DATE) diagnostic software that can potentially provide a numerical score for the likelihood of birth defects in an individual as being caused by exposure to thalidomide and to provide a differential diagnosis based on the pattern of malformation.
Assuntos
Deformidades Congênitas dos Membros/induzido quimicamente , Deformidades Congênitas dos Membros/diagnóstico , Teratogênicos/farmacologia , Talidomida/efeitos adversos , Algoritmos , Diagnóstico Diferencial , Feminino , História do Século XX , História do Século XXI , Humanos , GravidezRESUMO
Objective: To analysis teratogenic effect of GDC-0449 to fetus and set up the animal model of GDC-0449 induced oromandibular limb hypogenesis in mouse for further research of its pathogenesis. Methods: Twenty-seven pregnant Institute of Cancer Research (ICR) mice were randomly divided into: control group, embryonic day 8.5 (E8.5) exposed groups, E9.5 exposed groups, E10.5 exposed groups, E11.5 exposed groups, E12.5 exposed groups, E13.5 exposed groups, E14.5 exposed groups and E15.5 exposed groups. Each group had 3 mice. Exposed groups were treated with the Hedgehog pathway antagonist GDC-0449 at a single dose 150 mg/kg by oral gavage from E8.5 to E15.5. At E16.5, embryonic phenotypes were analyzed in detail by stereo microscope and histology. After establish an optimal dysmorphogenic concentration, 6 pregnant ICR mice were randomly divided into control group and the optimal group, embryonic phenotypes were analyzed by whole-mount skeletal staining and micro-computed tomography at E18.5. Results: The mice were exposed to GDC-0449 on E11.5 and E12.5 had a high incidence of cleft palate. GDC-0449 exposed between E9.5 and E10.5 caused craniofacial and limb dysmorphology, including micrognathia, microglossia, ectrodactylia, partial anodontia and cleft palate. Most interestingly, these are extremely similar to oromandibular limb hypogenesis syndrome. Conclusions: The results of this study indicate that GDC-0449 can be used to induce micrognathia, microglossia, ectrodactylia, partial anodontia and cleft palate. This work established a novel mouse model for oromandibular limb hypogenesis.
Assuntos
Anilidas/toxicidade , Fissura Palatina/induzido quimicamente , Anormalidades Craniofaciais/induzido quimicamente , Modelos Animais de Doenças , Proteínas Hedgehog/antagonistas & inibidores , Deformidades Congênitas dos Membros/induzido quimicamente , Piridinas/toxicidade , Animais , Feminino , Idade Gestacional , Camundongos , Camundongos Endogâmicos ICR , Micrognatismo/induzido quimicamente , Fenótipo , Gravidez , Distribuição Aleatória , Doenças da Língua/induzido quimicamente , Microtomografia por Raio-XRESUMO
Thalidomide notoriously caused severe birth defects, particularly to the limbs, in those exposed in utero following maternal use of the drug to treat morning sickness. How the drug caused these birth defects remains unclear. Many theories have been proposed including actions on the forming blood vessels. However, thalidomide survivors also have altered nerve patterns and the drug is known for its neurotoxic actions in adults following prolonged use. We have previously shown that CPS49, an anti-angiogenic analog of thalidomide, causes a range of limb malformations in a time-sensitive manner in chicken embryos. Here we investigated whether CPS49 also is neurotoxic and whether effects on nerve development impact upon limb development. We found that CPS49 is neurotoxic, just like thalidomide, and can cause some neuronal loss late developing chicken limbs, but only when the limb is already innervated. However, CPS49 exposure does not cause defects in limb size when added to late developing chicken limbs. In contrast, in early limb buds which are not innervated, CPS49 exposure affects limb area significantly. To investigate in more detail the role of neurotoxicity and its impact on chicken limb development we inhibited nerve innervation at a range of developmental timepoints through using ß-bungarotoxin. We found that neuronal inhibition or ablation before, during or after limb outgrowth and innervation does not result in obvious limb cartilage patterning or number changes. We conclude that while CPS49 is neurotoxic, given the late innervation of the developing limb, and that neuronal inhibition/ablation throughout limb development does not cause similar limb patterning anomalies to those seen in thalidomide survivors, nerve defects are not the primary underlying cause of the severe limb patterning defects induced by CPS49/thalidomide.
Assuntos
Inibidores da Angiogênese/toxicidade , Padronização Corporal/efeitos dos fármacos , Desenvolvimento Embrionário/efeitos dos fármacos , Deformidades Congênitas dos Membros/induzido quimicamente , Crescimento Neuronal/efeitos dos fármacos , Teratogênicos/toxicidade , Talidomida/análogos & derivados , Animais , Bungarotoxinas/farmacologia , Embrião de Galinha , Extremidades/embriologia , Extremidades/inervação , Feminino , Botões de Extremidades/inervação , Camundongos , Camundongos Endogâmicos C57BL , Síndromes Neurotóxicas , Talidomida/toxicidadeRESUMO
Congenital malformations might occur because of environmental or genetic factors, and sometimes occur because of unknown causes. Acetazolamide is a carbonic anhydrase inhibitor that is used to treat idiopathic intracranial hypertension, glaucoma, and epilepsy. The use of acetazolamide has not been recommended for pregnant women because of reported teratogenic risks. Congenital malformations, such as ectrodactyly, syndactyly, cleft lip/palate, and retarded incisor teeth development, have been reported in experimental animals. However, tooth agenesis due to the use of acetazolamide has not been reported yet. Oligodontia is a severe type of tooth agenesis involving six or more congenitally missing teeth. The causes of oligodontia are attributed to environmental factors, such as irradiation, drugs, trauma, tumors, infection, genetic factors, or a combination. There is no credible evidence of undesirable effects of acetazolamide use in human pregnancy. However, we report a case of a 12-year-old Saudi boy who was exposed to maternal acetazolamide (1,000 mg/day) for treatment of idiopathic intracranial hypertension before pregnancy, during the first trimester, and throughout the pregnancy. This treatment might have resulted in some congenital malformations, such as ectrodactyly, syndactyly, and oligodontia.
Assuntos
Anormalidades Múltiplas/induzido quimicamente , Acetazolamida/efeitos adversos , Acetazolamida/uso terapêutico , Lesões Pré-Concepcionais/induzido quimicamente , Complicações na Gravidez/tratamento farmacológico , Pseudotumor Cerebral/tratamento farmacológico , Acetazolamida/administração & dosagem , Criança , Feminino , Humanos , Deformidades Congênitas dos Membros/induzido quimicamente , Masculino , Gravidez , Sindactilia/induzido quimicamenteRESUMO
Possible teratogenicity of 3 different asbestos (crocidolite, chrysotile and amosite) was assessed in CD1(ICR) mice. Dams on day 9 of gestation were given a single intraperitoneal administration at dose of 40 mg/kg body weight of asbestos suspended in 2% sodium carboxymethyl cellulose solution in phosphate buffered saline, while dams in the control group were given vehicle (10 ml/kg body weight). Dams and fetuses were examined on day 18 of gestation. To compare with the control group, the mean percentage of live fetuses in implantations in the group given crocidolite and the incidence of dams with early dead fetuses in the groups given chrysotile or amosite were increased. While no external or skeletal malformation was observed in the control group, the incidence of external malformation (mainly reduction deformity of limb) in the group given amosite, and the incidences of skeletal malformation (mainly fusion of vertebrae) in the all dosed groups were significantly increased. The result indicated that asbestos (crocidolite, chrysotile and amosite) have fetotoxicity and teratogenicity in mice.
Assuntos
Amianto Amosita/toxicidade , Asbesto Crocidolita/toxicidade , Asbestos Serpentinas/toxicidade , Feto/anormalidades , Feto/efeitos dos fármacos , Deformidades Congênitas dos Membros/induzido quimicamente , Anormalidades Musculoesqueléticas/induzido quimicamente , Teratogênese/efeitos dos fármacos , Anormalidades Múltiplas , Animais , Amianto Amosita/administração & dosagem , Asbesto Crocidolita/administração & dosagem , Asbestos Serpentinas/administração & dosagem , Feminino , Idade Gestacional , Incidência , Injeções Intraperitoneais , Deformidades Congênitas dos Membros/epidemiologia , Troca Materno-Fetal , Camundongos , Camundongos Endogâmicos ICR , Anormalidades Musculoesqueléticas/epidemiologia , Gravidez , Organismos Livres de Patógenos EspecíficosRESUMO
Effects on postnatal development of Swiss albino mice exposed to nickel (Ni(2+)) ions as nickel chloride haxahydrate (NiCl2·6H2O) during the gestation periods were evaluated in this study. Administration of Ni to pregnant females by gavage (46.125, 92.25, and 184.5 mg Ni/kg body weight (b.w.)) at doses below median lethal dose during 0-5 (preimplantation period), 6-13 (organogenetic period), and 14-18 days (fetal period) postconception. The dams were allowed to deliver and raise their pups. Significant (p < 0.05) decrease in litter size was observed after 184.5 mg Ni/kg b.w. during the three gestation periods particularly from preimplantation period as compared to organogenetic and fetal periods in comparison with the control group. Exposure to 184.5 mg Ni/kg b.w. during fetal period revealed higher mortality as compared to organogenetic period. Exposure to 184.5 mg Ni/kg b.w. increased the eye, limb, and tail anomalies during organogenetic period. Gestation index from preimplantation period was low at all the doses. Live birth index decreased during preimplantation and organogenetic periods after 184.5 mg Ni/kg b.w. The viability and weanling of pups decreased during all periods after 92.25 and 184.5 mg Ni/kg b.w. doses. A dose-dependent highly significant (p < 0.01) decrease in the body weight of offspring from day 0 to 6 weeks of age at all the doses during different gestation periods were observed. Maximum body weight decrease was observed in offspring from organogenetic period. This study concludes that young ones are vulnerable during different gestational and lactation period which indicates that Ni ingested by mothers constitutes a great threat to the progeny.
Assuntos
Anormalidades Induzidas por Medicamentos/etiologia , Níquel/toxicidade , Animais , Peso Corporal/efeitos dos fármacos , Anormalidades do Olho/induzido quimicamente , Feminino , Deformidades Congênitas dos Membros/induzido quimicamente , Tamanho da Ninhada de Vivíparos/efeitos dos fármacos , Masculino , Troca Materno-Fetal , Camundongos , Gravidez , Efeitos Tardios da Exposição Pré-Natal , Cauda/anormalidadesRESUMO
The tumor suppressor protein p53 is a powerful regulator of the embryo's susceptibility to diverse teratogenic stimuli, functioning both as a teratogenesis inducer and suppressor. However, the targets that p53 engages to fulfill its functions remain largely undefined. We asked whether the microRNA (miRNA) miR-34 family, identified as one of the main targets of p53, mediates its function as a teratogenesis inducer. For this, pregnant ICR-, p53- and miR-34a-deficient mice, as well as rats, were exposed to 5-aza-2'-deoxycytidine (5-aza), a teratogen inducing limb reduction anomalies (LRA) of the hindlimbs in mice and either the hindlimbs or forelimbs in rats. Using hind- and forelimb buds of 5-aza-exposed embryos, we identified that the miR-34 family members are the most upregulated miRNAs in mouse and rat limb buds, with their increase level being significantly higher in limb buds destined for LRA. We showed that p53 mediates the 5-aza-induced miR-34 transcription followed by met proto-oncogene and growth-arrest-specific 1 target suppression in embryonic limb buds. We demonstrated that p53 regulates the teratogenic response to 5-aza acting as a teratogenesis inducer albeit miR-34a deletion does not affect the susceptibility of mice to 5-aza. Overall, our study thoroughly characterizes the expression and regulation of miR-34 family in teratogen-resistant and teratogen-sensitive embryonic structures and discusses the involvement of epigenetic miRNA-mediated pathway(s) in induced teratogenesis.
Assuntos
Anormalidades Induzidas por Medicamentos/metabolismo , Botões de Extremidades/efeitos dos fármacos , Deformidades Congênitas dos Membros/induzido quimicamente , MicroRNAs/metabolismo , Teratogênicos/toxicidade , Proteína Supressora de Tumor p53/metabolismo , Animais , Azacitidina/administração & dosagem , Azacitidina/análogos & derivados , Azacitidina/toxicidade , Decitabina , Relação Dose-Resposta a Droga , Resistência a Medicamentos , Feminino , Desenvolvimento Fetal/efeitos dos fármacos , Perfilação da Expressão Gênica , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Heterozigoto , Botões de Extremidades/anormalidades , Botões de Extremidades/metabolismo , Deformidades Congênitas dos Membros/metabolismo , Masculino , Camundongos Endogâmicos ICR , Camundongos Knockout , Gravidez , Ratos Sprague-Dawley , Proteína Supressora de Tumor p53/genética , Regulação para Cima/efeitos dos fármacosRESUMO
A case of esophageal atresia associated with a foregut duplication cyst is reported and the literature reviewed. This is the first documented occurrence in conjunction with Down syndrome and the second case where both anomalies were treated at the initial surgery.
Assuntos
Anormalidades Múltiplas/patologia , Síndrome de Down/patologia , Atresia Esofágica/patologia , Cisto Esofágico/congênito , Fístula Traqueoesofágica/congênito , Fístula Traqueoesofágica/patologia , Anormalidades Múltiplas/cirurgia , Canal Anal/anormalidades , Animais , Broncoscopia , Modelos Animais de Doenças , Doxorrubicina/toxicidade , Atresia Esofágica/cirurgia , Cisto Esofágico/embriologia , Cisto Esofágico/cirurgia , Esofagoplastia , Esôfago/anormalidades , Feminino , Cardiopatias Congênitas/induzido quimicamente , Comunicação Interventricular/patologia , Humanos , Achados Incidentais , Recém-Nascido , Rim/anormalidades , Deformidades Congênitas dos Membros/induzido quimicamente , Roedores , Coluna Vertebral/anormalidades , Toracotomia , Traqueia/anormalidades , Fístula Traqueoesofágica/cirurgiaRESUMO
In utero exposure to valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, causes neural tube, heart, and limb defects. Valpromide (VPD), the amide derivative of VPA, does not inhibit HDAC activity and is a weak teratogen in vivo. The detailed mechanism of action of VPA as a teratogen is not known. The goal of this study was to test the hypothesis that VPA disrupts regulation of the expression of genes that are critical in chondrogenesis and osteogenesis during limb development. Murine gestation day-12 embryonic forelimbs were excised and exposed to VPA or VPD in a limb bud culture system. VPA caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its HDAC inhibitory effect. The signaling of both Sox9 and Runx2, key regulators of chondrogenesis, was downregulated by VPA. In contrast, VPD had little effect on limb morphology and no significant effect on HDAC activity or the expression of marker genes. Thus, VPA exposure dysregulated the expression of target genes directly involved in chondrogenesis and osteogenesis in the developing limb. Disturbances in these signaling pathways are likely to be a consequence of HDAC inhibition because VPD did not affect their expressions.
Assuntos
Inibidores de Histona Desacetilases/toxicidade , Botões de Extremidades/efeitos dos fármacos , Deformidades Congênitas dos Membros/induzido quimicamente , Organogênese/efeitos dos fármacos , Efeitos Tardios da Exposição Pré-Natal/induzido quimicamente , Ácido Valproico/análogos & derivados , Animais , Western Blotting , Células Cultivadas , Condrogênese/efeitos dos fármacos , Condrogênese/genética , Subunidade alfa 1 de Fator de Ligação ao Core/genética , Relação Dose-Resposta a Droga , Feminino , Membro Anterior/citologia , Membro Anterior/efeitos dos fármacos , Membro Anterior/embriologia , Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos , Histona Desacetilases/metabolismo , Botões de Extremidades/citologia , Botões de Extremidades/embriologia , Deformidades Congênitas dos Membros/embriologia , Deformidades Congênitas dos Membros/genética , Camundongos , Camundongos Endogâmicos , Organogênese/genética , Osteogênese/efeitos dos fármacos , Osteogênese/genética , Gravidez , Efeitos Tardios da Exposição Pré-Natal/genética , Reação em Cadeia da Polimerase em Tempo Real , Fatores de Transcrição SOXB1/genética , Ácido Valproico/toxicidadeAssuntos
Adenocarcinoma/induzido quimicamente , Dietilestilbestrol/toxicidade , Deformidades Congênitas dos Membros/induzido quimicamente , Síndrome da Rubéola Congênita/virologia , Teratogênicos/toxicidade , Talidomida/toxicidade , Adolescente , Adulto , Feminino , Humanos , Achados Incidentais , Gravidez , Vírus da Rubéola/patogenicidadeRESUMO
Thalidomide was originally developed in 1954 as a sedative that was commonly used to ameliorate morning sickness. However, thalidomide exposure during the first trimester of pregnancy caused multiple birth defects (e.g. phocomelia and amelia), affecting ≈ 10,000 children worldwide in the late 1950s and early 1960s. Thalidomide is now recognized as a clinically effective, albeit strictly restricted, drug for the treatment of leprosy and multiple myeloma. Investigators have studied thalidomide teratogenicity for half a century, proposing over 30 hypotheses to account for its actions. Among these, the anti-angiogenesis and oxidative stress models have gained widespread support. Nonetheless, the precise molecular mechanisms and direct targets of thalidomide have not heretofore been elucidated. We developed ferrite-glycidyl methacrylate beads that enable magnetic separation and efficient purification of ligand-binding molecules; the beads were recently employed to identify cereblon as a primary target of thalidomide. Cereblon forms an E3 ubiquitin ligase complex with DDB1, Cul4A, and Roc1, which is important for the expression of fibroblast growth factor 8, an essential regulator of limb development. Expression of a drug binding-deficient mutant of cereblon suppressed thalidomide-induced effects in zebrafish and chicks. This suggests that thalidomide downregulates fibroblast growth factor 8 expression and induces limb malformation by binding to wild-type cereblon, inhibiting the function of the associated E3 ubiquitin ligase. The present review summarizes the teratogenicity of thalidomide, including existing models for its mode of action, and discusses the identification of cereblon as a key molecule for deciphering the longstanding mystery of thalidomide teratogenicity.
Assuntos
Mieloma Múltiplo/tratamento farmacológico , Teratogênicos/farmacologia , Talidomida/efeitos adversos , Proteínas Adaptadoras de Transdução de Sinal , Animais , Embrião de Galinha , Feminino , Fator 8 de Crescimento de Fibroblasto/metabolismo , Humanos , Deformidades Congênitas dos Membros/induzido quimicamente , Metacrilatos/química , Neovascularização Patológica , Estresse Oxidativo , Peptídeo Hidrolases/metabolismo , Gravidez , Ubiquitina/química , Ubiquitina-Proteína Ligases/metabolismo , Peixe-ZebraRESUMO
OBJECTIVE: To compare the distribution of congenital anomalies within the VACTERL association (vertebral defects, anal atresia, cardiac, tracheoesophageal, renal, and limb abnormalities) between patients exposed to tumor necrosis factor-α (TNF-α) antagonist and the general population. METHODS: Analysis for comparison of proportional differences to a previous publication between anomaly subgroups, according to subgroup definitions of the European Surveillance of Congenital Anomalies (EUROCAT), a population-based database. RESULTS: Most EUROCAT subgroups belonging to the VACTERL association contained only one or 2 records of TNF-α antagonist exposure, so comparison of proportions was imprecise. Only the category "limb abnormalities" showed a significantly higher proportion in the general population. CONCLUSION: The high number of congenital anomalies belonging to the VACTERL association from a report of pregnancies exposed to TNF-α antagonists could not be confirmed using a population-based congenital anomaly database.
Assuntos
Anormalidades Induzidas por Medicamentos/epidemiologia , Cardiopatias Congênitas/induzido quimicamente , Cardiopatias Congênitas/epidemiologia , Fatores Imunológicos/efeitos adversos , Deformidades Congênitas dos Membros/induzido quimicamente , Deformidades Congênitas dos Membros/epidemiologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Anormalidades Induzidas por Medicamentos/classificação , Anormalidades Induzidas por Medicamentos/fisiopatologia , Adulto , Canal Anal/anormalidades , Estudos de Coortes , Bases de Dados Factuais , Esôfago/anormalidades , Europa (Continente)/epidemiologia , Feminino , Humanos , Recém-Nascido , Rim/anormalidades , Gravidez , Efeitos Tardios da Exposição Pré-Natal , Coluna Vertebral/anormalidades , Traqueia/anormalidades , Fator de Necrose Tumoral alfa/fisiologiaRESUMO
The treatment of pregnant women with chemotherapeutic drugs leads to congenital malformations in 10-20% of newborn children. We present a case of an ongoing 19-week-long pregnancy which was diagnosed in a 39-year-old woman who was being treated with CEF (cyclophosphamide, epirubicin, 5-fluorouracil) chemotherapy for an infiltrating ductal carcinoma of the breast. After termination of the pregnancy, subsequent examination of the fetus revealed micrognathia and bilateral malformations of the hands and feet. The peak exposure of the fetus to the chemotherapeutic agents was in the 5th to 6th week of the pregnancy. Both the nature of the malformations and the timing of the administration of chemotherapy are similar to another case reported previously. We conclude that chemotherapy treatments with CEF in the 5th to 6th week of pregnancy specifically generate hand and foot abnormalities and micrognathia, which is consistent with an inhibition of proliferation, leading to cell death at this embryonic stage.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Deformidades Congênitas dos Membros/induzido quimicamente , Micrognatismo/induzido quimicamente , Adulto , Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem , Carcinoma Ductal de Mama/tratamento farmacológico , Ciclofosfamida/administração & dosagem , Ciclofosfamida/efeitos adversos , Epirubicina/administração & dosagem , Epirubicina/efeitos adversos , Feminino , Fluoruracila/administração & dosagem , Fluoruracila/efeitos adversos , Humanos , Masculino , Gravidez , Complicações Neoplásicas na Gravidez/tratamento farmacológico , Primeiro Trimestre da GravidezRESUMO
Thalidomide is a powerful treatment for inflammatory and cancer-based diseases. However, its clinical use remains limited due to its teratogenic properties, which primarily affect limb development. A prerequisite for overcoming these limitations is to understand the cellular and molecular mechanisms underlying thalidomide teratogenicity, which involve induction of oxidative stress, suppression of ubiquitin-mediated protein degradation and disruption of angiogenesis. Here, we discuss the hypothesis that thalidomide-induced limb teratogenicity is primarily based on the generation of nuclear oxidative stress with subsequent induction of transient apoptosis in the outgrowing limb bud. To this end, we establish a model of the signaling network regulating cell proliferation, survival and endogenous apoptosis-induction required for correct limb outgrowth and patterning. We then summarize data showing how thalidomide interferes with this signaling network: thalidomide inhibits the activity of the redox-sensitive transcription factor NF-κB, shifts the balance of fibroblast growth factors and bone morphogenetic proteins (Bmps) towards pro-apoptotic Bmps, and suppresses Wnt/ß-catenin- and Akt-dependent survival signaling in the limb bud. Consequently, prechondrogenic precursor cells that determine skeletal elements are eliminated leading to the development of truncated limbs. We further discuss the involvement of thalidomide effects on ubiquitin-mediated protein degradation and angiogenesis in the induction of apoptosis in the limb bud. Finally, we discuss the paradox that the embryonic molecular pathology induced by thalidomide suggests this drug as a candidate for therapeutic application in idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease characterized by downregulation of Bmp signaling, increased Wnt and Akt activity, and apoptosis resistance.
Assuntos
Apoptose , Fibrose Pulmonar Idiopática/tratamento farmacológico , Deformidades Congênitas dos Membros/induzido quimicamente , Teratogênicos/toxicidade , Talidomida/toxicidade , Animais , Modelos Animais de Doenças , Extremidades/crescimento & desenvolvimento , NF-kappa B/metabolismo , Estresse Oxidativo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/efeitos dos fármacos , Talidomida/uso terapêutico , Proteínas Wnt/metabolismoRESUMO
We investigated the teratogenic effect of an ethylene glycol-methyl cellosolve mixture on gestating Wistar rats, that received a daily intraperitoneal dose of different concentration of the mixture on day 8 of gestation until day 20. Multivariate analysis and Post-Hoc Bonferroni tests were used and relative risk and attributable fraction were calculated. In rats treated with the mixture the number of live fetuses decreased and reabsorptions increased with increasing concentrations of the mixture, as well as the number of abnormal fetuses. Abnormalities consisted mainly in atypical craniofacial morphology, protruding tongue, edema, signs of growth delay and shorter limbs, their frequency and severity increased at higher concentrations of the mixture. We conclude that the ethylene glycol-methyl cellosolve mixture possesses a higher teratogenic potential than each of its constituents separately, producing external fetal abnormalities, growth delay, and increased fetal death.
Se investigó el efecto teratogénicos de una mezcla de etilenglicol y metilcelosolve en ratas gestantes, las cuales recibieron por vía intraperitoneal una dosis diaria, a diferentes concentraciones de la mezcla, del día 8 al día 20 de gestación. Se utilizaron las pruebas de análisis multivariado y Post-Hoc de Bonferroni, y se calcularon el riesgo relativo y la fracción atribuible. En las ratas tratadas con la mezcla el número de fetos vivos disminuyó y las reabsorciones y el número de fetos anormales aumentaron a mayor concentración de los solventes. Las anormalidades fetales consistieron principalmente en morfología atípica craneofacial, protrusión de la lengua, edema, signos de retraso de crecimiento y acortamiento de extremidades, y su frecuencia y severidad se incrementó a mayor concentración de la mezcla. Concluimos que la mezcla de etilenglicol-metilcelosolve tiene mayor efecto teratogénico que cuando actúan cada uno de los solventes por separado, produciendo anormalidades fetales externas, retraso del crecimiento y aumento de muerte fetal.
Assuntos
Animais , Feminino , Gravidez , Ratos , Feto/anormalidades , Feto , Etilenoglicóis/administração & dosagem , Teratogênicos/toxicidade , Anormalidades Induzidas por Medicamentos , Análise de Variância , Anormalidades Craniofaciais/induzido quimicamente , Deformidades Congênitas dos Membros/induzido quimicamente , Etilenoglicol/administração & dosagem , Ratos WistarRESUMO
BACKGROUND: In a large number of studies, members of the microRNA (miRNA)-34 family such as miRNA-34a, miRNA-34b, miRNA-34c, as well as miRNA-125b and miRNA-155, have been shown to be regulators of apoptosis. The ability of these miRNAs to perform this function is mainly attributed to their ability to interact with the p53 tumor suppressor, which is a powerful regulator of the teratologic susceptibility of embryos. We chose to explore whether miRNA-34a/b/c, miRNA-125b and miRNA-155 may play a role in teratogenesis by using p53+/- pregnant mice treated with cyclophosphamide (CP) as a model. We evaluated how CP-induced alterations in the expression of these miRNAs in the embryonic limbs correlate with embryonic p53 genotype and CP-induced limb phenotypes. RESULTS: The limbs of p53 positive embryos were more sensitive to CP-induced teratogenic insult than the limbs of p53 negative embryos. The hindlimbs were more severely affected than the forelimbs. Robust miRNA-34a expression was observed in the fore- and hindlimbs of p53+/+ embryos exposed to 12.5 mg/kg CP. The dose of 20 mg/kg CP induced almost a two-fold increase in the level of miRNA-34a expression as compared to that exhibited by p53+/+ embryos exposed to a lower dose. Increased miRNA-34b and miRNA-34c expression was also observed. Of note, this dose activated miRNA-34a and miRNA-34c in the forelimbs of p53-/- embryos. When embryos were exposed to 40 mg/kg CP, the expression pattern of the miRNA-34a/b/c was identical to that registered in the limbs of embryos exposed to 20 mg/kg CP. However, this dose suppressed miRNA-125b and miRNA-155 expression in the fore- and hindlimbs of p53+/+ embryos. CONCLUSION: This study demonstrates that teratogen-induced limb dysmorphogenesis may be associated with alterations in miRNA-34, miRNA-125b and miRNA-155 expression. It also suggests for the first time that p53-independent mechanisms exist contributing to teratogen-induced activation of miRNA-34a and miRNA-34c. At the same time, teratogen-induced suppression of miRNA-125b and miRNA-155 expression may be p53 dependent. The analysis of correlations between the expression pattern of the tested miRNAs and CP induced limb phenotypes implies that miRNAs regulating apoptosis may differ from each other with respect to their functional role in teratogenesis: some miRNAs act to protect embryos, whereas other miRNAs boost a teratogen-induced process of maldevelopment to induce embryonic death.